Novartis Wants More Time To Answer EMA’s Zolgensma Questions
Executive Summary
Novartis unit AveXis is one of several companies seeking extra time to address questions the European Medicines Agency has regarding their marketing applications. The company says it could get a decision on whether the product should be approved in the EU by year-end.
You may also be interested in...
Critical Juncture In Zolgensma EU Market Quest
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
All Or Nothing: Paratek Withdraws EU Filing For Nuzyra
A month after being asked to attend an oral explanation meeting with the European Medicines Agency, Paratek Pharmaceuticals has decided to withdraw the EU marketing application for its broad spectrum antibiotic, Nuzyra. The company is one of two drug sponsors that has withdrawn an EU marketing application in October.
Novartis Says SMA Baby Death Not Due To Zolgensma
The Swiss major has new data on its SMA gene therapy which has been found not to be the cause of the death of a six-month-old patient earlier this year.